Iris (IRIS) Enters JV for 3GEMS Hematology Analyzer Development
Tweet
Share
E-mailGet Alerts IRIS Hot Sheet
Join SI Premium – FREE
Iris International, Inc. (Nasdaq: IRIS) has entered into a Joint Development Agreement with Fujirebio Inc. for the co-development of the IRIS 3GEMS Hematology Analyzer product line.
Terms of the agreement call for Fujirebio to contribute $6 million toward the costs of the Joint Development Program, with an initial payment of $500,000 upon signing of the agreement and the balance to be paid in installments during the course of the development period based upon the achievement of certain milestones.
Terms of the agreement call for Fujirebio to contribute $6 million toward the costs of the Joint Development Program, with an initial payment of $500,000 upon signing of the agreement and the balance to be paid in installments during the course of the development period based upon the achievement of certain milestones.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
- NeoVolta (NEOV) Appoints Ardes Johnson as New CEO
- SEE (SEE) and Ossid Create Strategic Partnership
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
